Berberine’s Inhibition of SASP via RXRα/PPARγ/NEDD4: Mechanistic Insights in Atherosclerosis

Study Background and Research Question

Atherosclerosis is a chronic inflammatory disease in which the accumulation of senescent cells—particularly macrophage-derived foam cells—contributes to plaque development and instability. A key feature of these aging cells is acquisition of the senescence-associated secretory phenotype (SASP), characterized by persistent secretion of pro-inflammatory cytokines, chemokines, and matrix remodeling enzymes. This so-called "inflammatory aging" has been implicated in the progression of age-related diseases, including cardiovascular disorders. However, the molecular mechanisms linking cellular senescence to chronic inflammation in atherosclerotic plaques remain incompletely defined. Berberine (BBR), a natural isoquinoline alkaloid, has previously shown anti-senescent and anti-inflammatory effects, but its precise mechanisms of action in the context of atherosclerosis were unclear. The reference study sets out to determine how BBR modulates SASP-driven inflammation, focusing on the RXRα/PPARγ/NEDD4 signaling pathway as a potential molecular axis underlying these effects.

Key Innovation from the Reference Study

The central innovation of the study is the identification of the RXRα/PPARγ/NEDD4 pathway as a critical mediator of BBR’s anti-inflammatory activity in atherosclerosis. Using a combination of single-cell transcriptomics, biochemical assays, and genetic manipulation, the authors demonstrate that BBR activates both RXRα and PPARγ, leading to upregulation of NEDD4, a ubiquitin ligase. This cascade promotes the ubiquitination and subsequent degradation of the GATA4/p62 complex, a key driver of SASP gene expression in macrophage-derived foam cells. The findings delineate a novel molecular mechanism by which BBR suppresses SASP-related inflammation and attenuates vascular aging.

Methods and Experimental Design Insights

The study employs a multi-tiered experimental approach:

• In vivo atherosclerosis model: ApoE^-/- mice were fed a high-fat diet to induce atherosclerotic plaques and then treated with BBR to assess changes in plaque morphology and systemic inflammation.
• Single-cell RNA sequencing: Human carotid artery plaques were analyzed to characterize the cellular composition and transcriptomic signatures of foam cells and other plaque-resident cells.
• Cellular assays: RAW264.7 macrophages and peritoneal macrophage-derived foam cells were evaluated for SASP marker expression, GATA4/p62 complex formation, and inflammatory cytokine secretion following BBR treatment.
• Pathway and mechanistic dissection: Smart-seq analysis and immunoprecipitation were used to examine the activation of the RXRα/PPARγ/NEDD4 axis. Lentiviral knockdown of RXRα in macrophages was performed to test the pathway’s necessity for BBR’s effects.
• Functional validation: The impact of BBR on ubiquitination and degradation of SASP-driving complexes was quantified, and the downstream consequences for inflammation were measured in both cell and animal models.

Core Findings and Why They Matter

The study presents several key findings:

• BBR treatment reduced the expression of SASP-related inflammatory proteins in both murine foam cells and atherosclerotic plaques, as observed through proteomic and histological analyses (reference).
• Single-cell RNA-seq confirmed that aging foam cells in human plaques exhibit a strong pro-inflammatory profile, reinforcing the clinical relevance of targeting SASP in atherosclerosis.
• Mechanistically, BBR activated RXRα and PPARγ, resulting in increased transcription of NEDD4. This led to enhanced ubiquitination and degradation of the GATA4/p62 complex, thereby suppressing SASP gene expression.
• Disruption of RXRα in macrophages abrogated the anti-inflammatory effects of BBR, highlighting the essential role of the RXRα/PPARγ immune complex in mediating these actions.

These findings suggest that pharmacological modulation of the RXRα/PPARγ/NEDD4 axis can serve as a targeted approach for mitigating chronic inflammation linked to senescent cells. Given the centrality of SASP-driven inflammation in atherosclerosis progression and plaque instability, the results provide a mechanistic rationale for further exploration of this pathway in cardiovascular disease therapeutics.

Comparison with Existing Internal Articles

The mechanistic focus on PPARγ and its modulation aligns with insights from several internal articles. For example, "T0070907: A Precision PPARγ Antagonist for Advanced Cell Assays" discusses how high-affinity PPARγ antagonists can dissect pathway-specific contributions in adipogenesis, cancer, and inflammation. While T0070907 is used primarily as a PPARγ antagonist, the reference study demonstrates the importance of PPARγ activation—rather than inhibition—in the anti-SASP effects of BBR. Furthermore, "Berberine Modulates RXRα/PPARγ/NEDD4 to Suppress SASP in Atherosclerosis" offers a concise overview of the same mechanism, emphasizing the translational potential of modulating this axis for vascular aging. Both internal and reference sources converge on the RXRα/PPARγ/NEDD4 pathway as a critical node for controlling inflammation and senescence in cardiovascular disease.

Limitations and Transferability

Despite the robust mechanistic elucidation, several limitations are notable:

• Species and model constraints: The primary animal data are from ApoE^-/- mice, which, while widely used, do not fully recapitulate human atherosclerosis.
• Complexity of pathway dynamics: The RXRα/PPARγ/NEDD4 axis may interact with other, as yet unidentified, regulatory networks that could influence outcomes in different cell types or tissues.
• Translational maturity: While the single-cell data from human plaques support the relevance of targeting foam cell SASP, direct evidence from clinical intervention studies is lacking.
• Pharmacological specificity: The anti-SASP effect observed with BBR is dependent on activation—not inhibition—of PPARγ, so results may differ with PPARγ antagonists or in contexts where PPARγ functions divergently.

Overall, while the pathway is clearly implicated in murine and ex vivo human models, further studies are required to assess the therapeutic utility and safety of manipulating this axis in clinical settings.

Protocol Parameters

• BBR dosing in vivo: ApoE^-/- mice were administered berberine at 100 mg/kg/day by oral gavage for 8 weeks to evaluate atherosclerotic plaque and inflammation outcomes.
• Foam cell induction: RAW264.7 macrophages and peritoneal macrophages were loaded with oxidized LDL (50 μg/mL, 24–48 hours) to generate foam cells for SASP assays.
• Lentiviral knockdown: RXRα expression in macrophages was silenced using pLVCD68-shRNA RXRα, with validation by qPCR and Western blot prior to in vivo or in vitro experiments.
• Smart-seq and transcriptomics: Single-cell RNA-seq was performed on isolated plaque cells to define transcriptomic changes in response to treatments.
• SASP marker analysis: Inflammatory cytokines (e.g., IL-6, TNF-α, MCP-1) were quantified by ELISA or qPCR; GATA4/p62 complex formation was evaluated by immunoprecipitation and ubiquitination assays.

Research Support Resources

For researchers aiming to dissect the dynamics of the PPARγ signaling pathway, especially in the context of SASP and atherosclerosis, high-affinity chemical tools are essential. T0070907 (SKU A4301) is a potent and selective PPARγ antagonist, with an IC50 and Ki of 1 nM, enabling precise modulation of PPARγ activity in cellular and biochemical assays. While the referenced study highlights the effects of PPARγ activation, antagonists like T0070907 can be deployed to clarify pathway specificity and off-target effects in mechanistic investigations. APExBIO provides detailed protocols and product information to support studies of PPARγ signaling, adipogenesis inhibition, and cell cycle regulation in disease models.